These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11405345)

  • 41. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease.
    Tarallo A; Damiano C; Strollo S; Minopoli N; Indrieri A; Polishchuk E; Zappa F; Nusco E; Fecarotta S; Porto C; Coletta M; Iacono R; Moracci M; Polishchuk R; Medina DL; Imbimbo P; Monti DM; De Matteis MA; Parenti G
    EMBO Mol Med; 2021 Nov; 13(11):e14434. PubMed ID: 34606154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Avalglucosidase alfa: First Approval.
    Dhillon S
    Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
    Young SP; Zhang H; Corzo D; Thurberg BL; Bali D; Kishnani PS; Millington DS
    Genet Med; 2009 Jul; 11(7):536-41. PubMed ID: 19521244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
    Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D
    Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pompe disease: current state of treatment modalities and animal models.
    Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE
    Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Report of the first Brazilian infantile Pompe disease patient to be treated with recombinant human acid alpha-glucosidase.
    Pereira SJ; Berditchevisky CR; Marie SK
    J Pediatr (Rio J); 2008; 84(3):272-5. PubMed ID: 18535739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
    Nicolino M; Byrne B; Wraith JE; Leslie N; Mandel H; Freyer DR; Arnold GL; Pivnick EK; Ottinger CJ; Robinson PH; Loo JC; Smitka M; Jardine P; Tatò L; Chabrol B; McCandless S; Kimura S; Mehta L; Bali D; Skrinar A; Morgan C; Rangachari L; Corzo D; Kishnani PS
    Genet Med; 2009 Mar; 11(3):210-9. PubMed ID: 19287243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Enzyme replacement therapy in a patient with Pompe disease].
    Fujikawa Y; Kinoshita S; Miyamoto Y; Nakayama T; Endo Y; Sasaki M
    No To Hattatsu; 2007 Sep; 39(5):383-6. PubMed ID: 17879614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
    Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
    Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
    Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
    Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
    Van Hove JL; Yang HW; Wu JY; Brady RO; Chen YT
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):65-70. PubMed ID: 8552676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
    Poelman E; Hoogeveen-Westerveld M; Kroos-de Haan MA; van den Hout JMP; Bronsema KJ; van de Merbel NC; van der Ploeg AT; Pijnappel WWMP
    J Pediatr; 2018 Apr; 195():236-243.e3. PubMed ID: 29428273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
    J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.
    Raben N; Ralston E; Chien YH; Baum R; Schreiner C; Hwu WL; Zaal KJ; Plotz PH
    Mol Genet Metab; 2010 Dec; 101(4):324-31. PubMed ID: 20801068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.